EMPEROR-Preserved and DELIVER have ushered in a new era for the treatment of heart failure with a preserved ejection fraction (HFpEF). In this commentary, we compare the characteristics and findings of these two trials and assess their implications for the broader management of the heart failure syndrome.
Copyright © 2022 Elsevier Inc. All rights reserved.